GlassScriptPhysician profile
Joseph Mark Pruner
NPI 1427493048
$19,456.21
in general payments reported to CMS, 2019-2025
40 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,090 · 2020: $3,743 · 2021: $1,381 · 2022: $1,443 · 2023: $2,917 · 2024: $4,655 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,666 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,665.80 |
| Education | $133.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,694.78 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $2,522.77 | 2021-2025 | |
| Amarin Pharma, INC. | $2,150.14 | 2019-2022 | |
| Amgen INC. | $1,444.47 | 2019-2025 | Repatha, Otezla, Evenity |
| Boston Scientific Corporation | $1,220.87 | 2022-2025 | Watchman Flx, Watchman Access System, Watchman |
| Astrazeneca Pharmaceuticals LP | $1,191.95 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,141.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $769.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $683.05 | 2019-2024 | Glassia |
| Allergan, INC. | $651.92 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $651.82 | 2019-2025 | Belsomra, Steglatro, Verquvo |
| Sanofi-Aventis U.S. LLC | $547.88 | 2019-2025 | |
| Pfizer INC. | $510.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.56 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $452.67 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $310.59 | 2019-2024 | Xarelto |
| Abbott Laboratories | $284.02 | 2020-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $258.14 | 2019-2025 | Veozah |
| Antares Pharma, INC. | $237.07 | 2024-2025 | Xyosted |
| Assertio Therapeutics, INC. | $234.40 | 2019-2020 | |
| Exact Sciences Corporation | $216.25 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $93.92 | 2020 | |
| Avanir Pharmaceuticals, INC. | $81.81 | 2019 | |
| Lundbeck LLC | $63.21 | 2024-2025 | Rexulti |
| Dexcom, INC. | $58.74 | 2023-2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $52.50 | 2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $51.29 | 2024 | Sotyktu, Eliquis |
| Halozyme INC | $46.91 | 2023 | |
| Azurity Pharmaceuticals, INC. | $45.26 | 2025 | Azmiro |
| Otsuka America Pharmaceutical, INC. | $42.63 | 2024 | Jynarque, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.59 | 2019 | |
| Aytu Biopharma, INC. | $41.08 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $33.10 | 2020-2024 | Contrave |
| Mdd US Operations, LLC | $25.50 | 2019-2020 | |
| Viatris Specialty LLC | $23.46 | 2025 | Yupelri |
| Endo Pharmaceuticals INC. | $20.37 | 2020 | |
| Dermira, INC. | $19.22 | 2020 | |
| Bardy Diagnostics, INC. | $18.32 | 2020 | |
| Esperion Therapeutics, INC. | $17.84 | 2020 | |
| Genentech USA, INC. | $14.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pruner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.